StarGen (SAR422459) / Oxford Biomedica - LARVOL DELTA

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=28 | Enrolling by invitation | Sponsor: Sanofi | Trial primary completion date: Mar 2022 ➔ Dec 2034

Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1 | N=28 | Enrolling by invitation | Sponsor: Oxford BioMedica

New P1 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1 | N=28 | Enrolling by invitation | Sponsor: Oxford BioMedica | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=46 | Recruiting | Sponsor: Sanofi | N=28 ➔ 46

Enrollment change • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=28 | Enrolling by invitation | Sponsor: Sanofi | Trial primary completion date: Sep 2032 ➔ Dec 2032

Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=28 | Enrolling by invitation | Sponsor: Sanofi | Trial primary completion date: Oct 2030 ➔ Mar 2022

Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=28 | Enrolling by invitation | Sponsor: Sanofi | Trial primary completion date: Nov 2033 ➔ Mar 2034

Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=28 | Enrolling by invitation | Sponsor: Oxford BioMedica | Trial primary completion date: Nov 2028 ➔ Oct 2030

Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=28 | Enrolling by invitation | Sponsor: Sanofi | Trial primary completion date: Dec 2034 ➔ Sep 2032

Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=28 | Enrolling by invitation | Sponsor: Sanofi | Trial primary completion date: Dec 2032 ➔ Nov 2033

Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=28 | Enrolling by invitation | Sponsor: Oxford BioMedica | Trial completion date: Nov 2028 ➔ Oct 2030

Trial completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=28 | Enrolling by invitation | Sponsor: Oxford BioMedica | Phase classification: P1 ➔ P1/2

Phase classification • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=28 | Recruiting | Sponsor: Sanofi | Enrolling by invitation ➔ Recruiting | Trial primary completion date: Mar 2034 ➔ Nov 2034

Enrollment status • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P2 | N=27 | Active, not recruiting | Sponsor: Sanofi | Phase classification: P1/2 ➔ P2

Phase classification • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=27 | Active, not recruiting | Sponsor: Sanofi | Trial completion date: Aug 2034 ➔ Aug 2033 | Trial primary completion date: Aug 2034 ➔ Aug 2033

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=27 | Active, not recruiting | Sponsor: Sanofi | Trial completion date: Aug 2033 ➔ Aug 2034 | Trial primary completion date: Aug 2033 ➔ Aug 2034

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=27 | Active, not recruiting | Sponsor: Sanofi | N=46 ➔ 27

Enrollment change • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=46 | Active, not recruiting | Sponsor: Sanofi | Trial completion date: Jun 2034 ➔ Aug 2033 | Trial primary completion date: Jun 2034 ➔ Aug 2033

Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=46 | Active, not recruiting | Sponsor: Sanofi | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration (clinicaltrials.gov) - P1/2 | N=46 | Enrolling by invitation | Sponsor: Sanofi | Recruiting ➔ Enrolling by invitation | Trial completion date: Feb 2035 ➔ Jun 2034 | Trial primary completion date: Feb 2035 ➔ Jun 2034

Enrollment status • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders

The Promising Prospective Technology for Biofuel Production with Mixed Cultures Using Sorghum Grain (Sorghum bicolor (L.) Moench) Grown in a Temperate Climate: Characteristics of Fermentation Factors and Volatile Compounds Analysis. (PubMed, J Agric Food Chem) - "Analyses revealed that the granular starch fermentation method (with Stargen 002) combined with mixed cultures yielded higher bioethanol by about an average of 5% compared to single cultures...Distillates from fermentation with mixed cultures contained higher amounts of volatile byproducts (9.04-11.38 g/L) than single bacterial cultures (4.10-6.68 g/L) but less than single yeast cultures (9.27-13.14 g/L). These findings indicate the potential of mixed cultures in granular starch fermentation, at the same time suggesting that challenges such as selecting microbial consortia, accelerating the process, and ensuring consistent yields must be solved for widespread industrial application."

Journal

Bioethanol production from sorghum grain with Zymomonas mobilis: Increasing the yield and quality of raw distillates. (PubMed, J Sci Food Agric) - "The study emphasizes the great potential of bioethanol production from sorghum with Z. mobilis using granular starch hydrolyzing enzyme Stargen 002, which leads to reduce water and energy consumption, especially when energy sources are strongly related to global climate change."

Journal

Three-year safety results of SAR422459 (EIAV-ABCA4) gene therapy in patients with ABCA4-associated Stargardt disease: An open-label dose-escalation phase I/IIa clinical trial, cohorts 1-5. (PubMed, Am J Ophthalmol) - "Subretinal treatment with EIAV-ABCA4 was well tolerated with only one case of ocular hypertension. No clinically significant changes in visual function tests were found to be attributable to the treatment. However, 27% of treated eyes showed exacerbation of RPE atrophy on FAF. There was significant reduction in macular flecks in one treated eye from the highest dose cohort. Additional follow-up and continued investigation in more patients will be required to fully characterize the safety and efficacy of EIAV-ABCA4."

Journal • P1/2 data • Gene Therapies • Glaucoma • Hematological Disorders • Inherited Retinal Dystrophy • Ophthalmology • Retinal Disorders

Structural and spectral properties of generative models for synthetic multilayer air transportation networks. (PubMed, PLoS One) - "Besides a thorough study of the topological aspects of the ATNs created by the three models, our major contribution lays on an unprecedented investigation of their spectral characteristics based on Random Matrix Theory and on their resilience analysis based on both site and bond percolation approaches. Results have shown that ANGEL outperforms STARGEN and BINBALL to better capture the complexity of real-world ATNs by featuring the unique properties of building a multiplex ATN layer by layer and of replicating layers with point-to-point structures alongside hub-spoke formations."

Journal

Conversion of Starchy Waste Streams into Polyhydroxyalkanoates Using Cupriavidus necator DSM 545. (PubMed, Polymers (Basel)) - "Cupriavidus necator DSM 545, a well-known producer of PHAs, was adopted in a simultaneous saccharification and fermentation (SSF) process through an optimized dosage of the commercial amylases cocktail STARGEN™ 002. Broken rice was found to be the most promising carbon source with PHAs levels of up to 5.18 g/L. This research demonstrates that rice and sweet potato waste are low-cost feedstocks for PHAs production, paving the way for the processing of other starchy materials into bioplastics."

Journal